Searched for
ANTI RETROVIRAL THERAPY
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Govt identifies 7 districts in Delhi, 11 in Haryana for priority HIV/AIDS interventionsThe Union Health Ministry is prioritising 219 districts for HIV/AIDS interventions. Haryana and Delhi are key focus areas. The National AID...
- Health Ministry implements HIV, AIDS ActThe act seeks to prevent and control the spread of HIV and AIDS and and creates mechanisms for redressing the complaints of persons infecte...
- Parliamentary panel asks health ministry to expedite setting up of anti-retroviral treatment centresThe panel has also asked the ministry to devise a mechanism for providing an expanded access to subsidised anti-retroviral therapy for poor...
- Hetero launches FDC combination of key HIV drugsThe FDC drug ‘Darunavir+Ritonavir’ is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in ...
- Biomarkers of cognitive impairment found in HIV patients: StudyNew York, Sep 25 (IANS) Using reliable biomarkers, researchers have found a unique epigenetic footprint which offers them insight into how ...
- AIDS epidemic can end by 2030: UNAIDSAIDS-related deaths have fallen by 42 per cent since 2004 -- the year that saw the largest number of deaths in the history of the epidemic.
- Early HIV treatment may save patients diagnosed with tuberculosisStarting anti-HIV treatment within two weeks of the diagnosis of tuberculosis improved survival among patients with both infections, a new ...
- Cipla awarded $188.95 million tender by Global Fund for ARV drugs to treat HIV/AIDSCipla has been awarded $188.95 million tender for anti-retrovirals drugs by Global Fund which would enable it to supply the medicines to ov...
- On World AIDS Day, Larsen & Toubro opens new anti-retroviral therapy centreThe centre, owned by the Municipal Corporation of Greater Mumbai (MCGM), has been built by L&T, which will also operate it.
- Cipla’s March quarter performance: Low margin business and high costs continueThe operating profit dropped 4% and operating margin contracted 530 bps to 16.8%. Net profit also declined by 6% over the year ago level.
- Glenmark US partner Salix gets USFDA nod for Crofelemer tabletUS Food and Drug Administration provided marketing approval to its partner in US, Salix Pharmaceuticals, for Crofelemer 125 mg delayed-rele...
- Cipla to develop formulation for HIV +ve children with DNDiCipla will work to produce an appropriate 4-in-1 combination sachet product for easy mixing into food or liquids such as water, juice, or b...
- US bio-pharma firm Gilead Sciences in pact with four Indian cosUS-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.
- Ranbaxy inks pact with Gilead for three generic HIV/AIDS drugsRanbaxy has entered into an agreement with US-headquartered Gilead Sciences to manufacture and market three new generic HIV/AIDS drugs.
- Drugs by Indian cos reduces cost of HIV first line treatmentGeneric anti-retroviral drugs manufactured by Indian cos have brought down the cost of first line treatment for HIV patients from $800 to $...
- Two new TB drugs enter advanced stages of clinical trialTwo new drugs against tuberculosis have reached the advanced stages of clinical trial and could be made available for use by 2012-2014.
- Matrix signs licensing deal with US coPharmacuetical company, Matrix Laboratories Ltd on Friday said it signed a licensing agreement with Gilead for manufacture and sale of a ge...
Load More
